Previous 10 | Next 10 |
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal models of adoptive cell therapy support the use of NX-0255 in the production o...
Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...
Nurix Therapeutics press release (NASDAQ:NRIX): FQ1 GAAP EPS of -$0.95 misses by $0.07. Revenue of $9.62M (+92.0% Y/Y) beats by $0.35M. Shares +0.29% AH. For further details see: Nurix Therapeutics GAAP EPS of -$0.95 misses by $0.07, revenue of $9.62M beats by $0.35M
Nurix Therapeutics (NASDAQ:NRIX): Q1 GAAP EPS of -$0.95 misses by $0.09. Revenue of $9.6M (+92% Y/Y) beats by $0.33M. Press release The increase in quarterly collaboration revenue was primarily due to the recognition of revenue as a cumulative catch up for activities satisfied in previous per...
Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Reports strong fin...
Nurix Therapeutics (NASDAQ:NRIX) dosed the first patient in its phase 1 trial of its drug-enhanced cell therapy DeTIL-0255 in patients with advanced gynecological malignancies including ovarian cancer, cervical cancer and endometrial cancer. The initiation of the company's firs...
SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a d...
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executi...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Nurix Therapeutics (NASDAQ:NRIX) said the UK Medicines and Healthcare products Regulatory Agency (MHRA) had awarded the innovative medicine designation for its therapy, NX-1607, to treat advanced solid tumors. The company plans to present the initial data from the Phase 1a study in mid-2...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...